{"nctId":"NCT03226392","briefTitle":"Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma","startDateStruct":{"date":"2017-10-31","type":"ACTUAL"},"conditions":["Asthma"],"count":704,"armGroups":[{"label":"QAW039","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: QAW039"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"QAW039","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of asthma (according to GINA 2016) for a period of at least 6 months.\n* Treated with medium dose inhaled corticosteroid (ICS), or high dose ICS, or low dose ICS plus long- acting beta agonist (LABA), or low dose ICS plus leukotriene receptor antagonist (LTRA), or medium dose ICS plus LABA for at least 3 months prior to Visit 1 and the doses have been stable for at least 4 weeks prior to Visit 1.\n* FEV1 of ≤85% for patients aged ≥18 years. FEV1 of ≤90% for patients aged 12 to \\<18 years.\n* Daytime asthma symptom score (0 to 6 scale) of ≥1 per day during 4 of the last 7 days of the placebo run- in period.\n* Total daily SABA use ≥1 puff per day during 4 of the last 7 days of the placebo run-in period.\n* Demonstrated reversible airway obstruction.\n* Asthma control questionnaire (ACQ) score ≥ 1.5.\n\nExclusion Criteria:\n\n* Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days, whichever is longer.\n* A resting QTcF (Fridericia) ≥450 msec (male) or\n\n  ≥460 msec (female).\n* Pregnant or nursing (lactating) women.\n* Serious co-morbidities.\n* Patients on \\>20 mg of simvastatin, \\> 40 mg of atorvastatin, \\>40 mg of pravastatin, or \\>2 mg of pitavastatin.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Pre-dose FEV1","description":"Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.126","spread":"0.00177"},{"groupId":"OG001","value":"0.157","spread":"0.0177"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Daytime Asthma Symptom Score","description":"Daytime asthma symptoms are evaluated through four questions and each of them will be rated on a scale of 0 to 6. Higher scores indicate more severe asthma-related symptoms. A mean score is calculated for the responses to 4 questions.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"0.034"},{"groupId":"OG001","value":"-0.45","spread":"0.034"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Number of Puffs of SABA Taken Per Day","description":"Daily use of SABA (the number of rescue medication puffs taken in the previous 12 hours) was recorded using a patient electronic diary (referred to as eDiary or eDiary/ePEF). Patients were instructed to routinely complete the patient diary twice daily - at the same time each morning and each evening, approximately 12 hours apart.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":"0.066"},{"groupId":"OG001","value":"-0.88","spread":"0.066"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Score","description":"AQLQ is a 32-item instrument administered as a self-assessment. AQLQ+12 is a modified version of AQLQ developed to measure functional impairments of participants aged 12-70 years. It is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Participants were asked to recall their experiences during the last 2 weeks and respond to each question on a 7-point scale (1=severe impairment, 7=no impairment), where higher scores indicated \"better quality of life.\" Overall AQLQ+12 score is the mean of all 32 responses.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"0.043"},{"groupId":"OG001","value":"0.72","spread":"0.043"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":352},"commonTop":["Asthma","Nasopharyngitis","Viral upper respiratory tract infection","Headache","Upper respiratory tract infection"]}}}